Review

Bilirubin metabolism and its role in atherosclerosis

Volume: 5 Number: 2 August 31, 2020
EN

Bilirubin metabolism and its role in atherosclerosis

Abstract

Hemoglobin is not an guiltless bystander of the pathophysiology in a number of atherosclerotic diseases. Heme, which is released from hemoglobin or other heme proteins, triggers various pathophysiological consequence, including heme stress as well as intracellular stress. Although heme serves key functions and is tightly controlled, high levels of free heme, which may occur in various pathophysiological conditions, are may hazardous via pro-oxidant, pro-inflammatory, and cytotoxic effects. Heme oxygenases are heat shock protein enzymes that use heme as a substrate and function as an essential antioxidant adaptive response by all human cells. A major function of heme oxygenases is clearance of heme that accumulate in tissues due to erythrocyte turnover. The potentially toxic free heme is converted by heme oxygenases into carbon monoxide, iron, and biliverdin, the latter of which is reduced to bilirubin. In literature the heme degradation pathway has been demonstrated to play a protective role against the development of atherosclerosis. Because growing evidence suggests that oxidative stress is involved in atherosclerosis. This review documents the roles of bilurubin in atherosclerosis and focuses on the clinical significance as a potential therapeutic target in atherosclerotic diseases, such as coronary artery disease.

Keywords

References

  1. Kang SJ, Leea C, Kruzliakb P. Effects of serum bilirubin on atherosclerotic processes. Annals of Medicine. 2014;46(3):138-47.
  2. Vítek L. The role of bilirubin in diabetes, metabolic syndrome, and cardiovascular diseases. Front Pharmacol. 2012;3:55.
  3. Lin Y, Wang S, Yang Z, Gao L, Zhou Z, Yu P, Wu B.Bilirubin alleviates alum-induced peritonitis through inactivation of NLRP3 inflammasome. Biomed Pharmacother. 2019;116:108973.
  4. Kang SJ, Lee C, Kruzliak P.Effects of serum bilirubin on atherosclerotic processes. Ann Med. 2014; 46(3):138-47.
  5. Yilmaz N, Cicek HK, Celik A, Davutoglu V. Diagnostic value of bilirubin concentrations compared with novel and traditional biomarkers in atherosclerosis with coronary artery disease. Saudi Med J. 2006;27(8):1262-4.
  6. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235(4792):1043–6.
  7. Wu TW, Fung KP, Yang CC. Unconjugated bilirubin inhibits the oxidation of human low density lipoprotein beter than Trolox. Life Sci. 1994;54(25):477-81.
  8. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A. 2002;99(25):16093–8.

Details

Primary Language

English

Subjects

​Internal Diseases

Journal Section

Review

Publication Date

August 31, 2020

Submission Date

March 7, 2020

Acceptance Date

July 14, 2020

Published in Issue

Year 1970 Volume: 5 Number: 2

Vancouver
1.Necat Yılmaz, Cemile Öz, Esin Eren, Seçkin Özgür Tekeli. Bilirubin metabolism and its role in atherosclerosis. Arch Clin Exp Med. 2020 Aug. 1;5(2):79-85. doi:10.25000/acem.699424